|
| Subclinical hyperthyroidism and CHD | Summary relative risk (95% CI)+ | Studies, n |
|
| Eligible study model | | |
| Random effects | 1.20 (1.02–1.42) | 9 |
| Fixed effects | 1.20 (1.02–1.41) | 9 |
| Stratified by mean age, y | | |
| <65 | 1.32 (0.98–1.77) | 4 |
| ≥65 | 1.14 (0.87–1.50) | 5 |
| <60 | 1.32 (0.98–1.77) | 4 |
| 60–79.9 | 1.14 (0.85–1.51) | 4 |
| ≥80 | 1.19 (0.49–2.94) | 1 |
| Stratified by TSH, mIU/L | | |
| 0.1–0.44 | 0.62 (0.21–1.86) | 1 |
| <0.1 | 0.96 (0.33–2.80) | 1 |
| Adjustments | | |
| Adjusted analyses or matching | 1.20 (1.02–1.42) | 9 |
| Adjusted for cardiovascular risk factors | 1.18 (0.94–1.49) | 6 |
| Excluding studies | | |
| Exclusion of studies with antithyroid drug recipients | 1.18 (0.98–1.41) | 7 |
| Exclusion of studies with particular population [42] | 1.21 (1.02–1.45) | 8 |
|
| Subclinical hyperthyroidism and total mortality | Summary relative risk (95% CI)+ | Studies, n |
|
| Eligible study model | | |
| Random effects | 1.27 (1.07–1.51) | 10 |
| Fixed effects | 1.36 (1.22–1.51) | 10 |
| Stratified by mean age, y | | |
| <65 | 1.62 (1.37–1.90) | 2 |
| ≥65 | 1.17 (0.98–1.40) | 8 |
| <60 | 1.62 (1.37–1.90) | 2 |
| 60–79.9 | 1.18 (0.96–1.44) | 7 |
| ≥80 | 1.08 (0.60–1.93) | 1 |
| Stratified by TSH, mIU/L | | |
| 0.1–0.44 | 0.45 (0.12–1.76) | 1 |
| <0.1 | 1.74 (0.78–3.87) | 1 |
| Adjustments | | |
| Adjusted analyses or matching | 1.27 (1.07–1.51) | 10 |
| Adjusted for cardiovascular risk factors | 1.23 (0.94–1.63) | 5 |
| Excluding studies | | |
| Exclusion of studies with antithyroid drug recipients | 1.26 (1.04–1.53) | 8 |
| Exclusion of studies with particular population [42] | 1.29 (1.07–1.54) | 9 |
|
| Subclinical hyperthyroidism and cardiovascular mortality | Summary relative risk (95% CI)+ | Studies, n |
|
| Eligible study model | | |
| Random effects | 1.12 (0.84–1.50) | 7 |
| Fixed effects | 1.10 (0.82–1.47) | 7 |
| Stratified by mean age, y | | |
| <65 | 0.84 (0.28–2.50) | 1 |
| ≥65 | 1.15 (0.85–1.55) | 6 |
| <60 | 0.84 (0.28–2.50) | 1 |
| 60–79.9 | 1.15 (0.84–1.58) | 5 |
| ≥80 | 1.11 (0.39–3.17) | 1 |
| Stratified by TSH, mIU/L | | |
| 0.1–0.44 | 0.47 (0.07–3.27) | 1 |
| <0.1 | 2.16 (0.74–6.34) | 1 |
| Adjustments | | |
| Adjusted analyses or matching | 1.12 (0.84–1.50) | 7 |
| Adjusted for cardiovascular risk factors | 0.98 (0.65–1.47) | 4 |
| Excluding studies | | |
| Exclusion of studies with antithyroid drug recipients | 1.13 (0.81–1.58) | 5 |
| Exclusion of studies with particular population [42] | 1.12 (0.83–1.52) | 6 |
|
